<DOC>
	<DOCNO>NCT02648035</DOCNO>
	<brief_summary>The purpose study evaluate percentage participant treat subcutaneous ( SC ) Tocilizumab still treatment 52 week factor play major role continuation treatment .</brief_summary>
	<brief_title>EMBRACE-SC : Observational Study Subcutaneous ( SC ) Tocilizumab Alone Combination With Conventional Disease-Modifying Antirheumatic Drugs ( cDMARDs ) Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Aged &gt; /= 18 year age rheumatoid arthritis ( RA ) treat physician make decision start subcutaneous ( SC ) Tocilizumab ( TCZ ) treatment accord approve label within 4 week prior enrolment . Participants receive Tocilizumab ( TCZ ) 4 week prior enrolment . Participants receive TCZ past treatment . Participants receive treatment investigational agent within 4 week ( 5 halflives investigational agent , whichever long ) start treatment TCZ SC . Participants history autoimmune disease joint inflammatory disease rheumatoid arthritis ( RA ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>